Georgia Homebuilder Launches What Could Be 2024’s First U.S. IPO
(Bloomberg) -- Smith Douglas Homes Corp. launched plans to raise as much as $161.5 million in an initial public offering that could be the first US listing of 2024.
With dozens of potential IPO candidates watching closely for a sign of a listings rebound, Smith Douglas Homes said in a filing Wednesday that it plans to sell almost 7.7 million shares for $18 to $21 each.
The filing follows one of the worst years for listings of the past decade, with only $26 billion raised on US exchanges, according to data compiled by Bloomberg. That was up slightly from 2022 but less than a twelfth of the record-setting $339 billion raised in 2021, the data show.
Listings are pending for more than 170 companies that have filed for IPOs in the past year. The plans of many would-be public companies stalled after a quartet of prominent offerings led by semiconductor designer Arm Holdings Plc in September failed to deliver the results sought by investors.
BrightSpring Health Services Inc., backed by KKR & Co., submitted its initial public filing on Tuesday, another sign of the market potentially warming. The home and community-based health-care services provider, which won't disclose proposed terms for the IPO until a later filing, was planning to seek to raise $1 billion in an IPO, Bloomberg News reported in September.
Smith Douglas Homes, based in Woodstock, Georgia, had home-closing revenue of almost $595 million for the nine months ended Sept. 30, according to its filing. The company's founding family will continue to control it after the IPO.
The offering is being led by JPMorgan Chase & Co., Bank of America Corp., RBC Capital Markets and Wells Fargo & Co. The company plans for its shares to trade under the symbol SDHC.
More stories like this are available on bloomberg.com
©2024 Bloomberg L.P.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.